about
Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challengesTuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapyRoutine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan childrenVirologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda.Opportunities for improving the efficiency of paediatric HIV treatment programmes.No difference in sexual behavior of adolescent girls following Human Papilloma Virus vaccination: a case study two districts in Uganda; Nakasongola and Luwero.Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.Factors influencing social self-disclosure among adolescents living with HIV in Eastern Africa.Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study.Perspectives of host faculty and trainees on international visiting faculty to paediatric academic departments in East Africa.A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries.Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe.Adherence to antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods: a prospective cohort study.Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda.HIV serostatus disclosure and lived experiences of adolescents at the Transition Clinic of the Infectious Diseases Clinic in Kampala, Uganda: a qualitative study.Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy.Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.Sexual risk reduction needs of adolescents living with HIV in a clinical care setting.Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.Subtype analysis of Cryptosporidium isolates from children in Uganda.Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus.Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda.Global Health: Preparation for Working in Resource-Limited Settings.Making Implementation Science Work for Children and Adolescents Living With HIVUtilization of "prevention of mother-to-child transmission" of HIV services by adolescent and young mothers in Mulago Hospital, Uganda
P50
Q27022471-C101E31E-EFB3-45E7-A9F2-8E7DE289D158Q28602123-EEA75A94-B076-4AB1-A814-1C18B29EFBBEQ30539434-73743294-FA64-4498-8E79-903B51849E09Q34039981-3CD42110-8B9F-4421-AB81-AE23AA77A292Q34640041-231013BE-8ADA-4520-B2FE-D559F76C4E7DQ35054163-C030C02A-3115-4C85-8A8A-93A266260CF3Q35092994-DD52A5EB-9E38-48B1-AC3C-14AB1EF1D727Q36386822-CFDA94E1-5AFB-485E-A405-74E9302B9442Q36388791-3E43B56E-B82A-4A00-9672-004942196882Q36699672-632B04BD-8621-40D9-B4E7-5B8C288A6134Q37659826-86CD63AF-6A92-49F2-8F6F-056F83F0643DQ38848311-4F2FD145-C66E-494D-893D-5C6B3CC9A760Q38850249-F25BA542-39CE-44CF-939B-887311852A24Q38866001-036E3275-D916-43E3-BF09-84EB1C6B4B24Q38867667-DA4B166D-2CCD-46E4-AEBC-0A4F2602197AQ38868876-3A6FADE0-3E5F-45A0-B4C4-10905F18D5A7Q38869000-08A1DC77-3BC6-4CF0-9ACF-FAE6E783360CQ38870389-BD7B3634-17B9-46A3-8B10-687DA7A6B717Q38871160-CDECB0D2-E839-4507-9501-3EBF17D56A54Q38871183-6361CF56-5435-491A-B54A-878A5A4DCBD3Q38876327-749415D0-23D0-4FF6-947C-E2DD8CCC2241Q38877618-EC2DBC95-0E0A-4CE1-A45F-F531C8D67B3AQ38878757-E98299AB-A7A2-4907-A7C2-ED3553D377CFQ38880216-D31FC197-F723-4741-B0EA-43F1C08008ACQ38881616-69010729-9A9E-405F-B94B-8FBE93018A5BQ46983743-A30EC2D4-3A29-47BD-9A57-E283312E7CC4Q56910410-599858B1-EC93-4343-8940-F42D542569ECQ59135857-F782249A-A15F-4715-9333-DDD8E97B95E0
P50
description
researcher ORCID ID = 0000-0003-2724-8287
@en
name
Sabrina Bakeera-Kitaka
@ast
Sabrina Bakeera-Kitaka
@en
Sabrina Bakeera-Kitaka
@es
Sabrina Bakeera-Kitaka
@nl
type
label
Sabrina Bakeera-Kitaka
@ast
Sabrina Bakeera-Kitaka
@en
Sabrina Bakeera-Kitaka
@es
Sabrina Bakeera-Kitaka
@nl
prefLabel
Sabrina Bakeera-Kitaka
@ast
Sabrina Bakeera-Kitaka
@en
Sabrina Bakeera-Kitaka
@es
Sabrina Bakeera-Kitaka
@nl
P21
P31
P496
0000-0003-2724-8287